参考文献/References:
［1］ 高亚明， 赵永强， 王书杰． 肝素诱导的血小板减少症发病率及其抗体阳性率调查［J］． 中华内科杂志， 2013， 52： 734- 736．
［2］ 田玉龙， 张曦彤． 下肢深静脉血栓介入治疗发生肝素诱导血小板减少伴血栓形成综合征一例［J］． 介入放射学杂志， 2012， 21： 53- 54．
［3］ Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin- induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence- based clinical practice guidelines［J］. Chest, 2012, 141: e495S- e530S.
［4］ Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin- induced thrombocytopenia in postoperative orthopedic patients［J］. Arch Intern Med, 2003, 163: 2518- 2524.
［5］ Martel N, Lee J, Wells PS. Risk for heparin- induced thrombocy- topenia with unfractionated and low- molecular- weight heparin thromboprophylaxis: a meta- analysis［J］. Blood, 2005, 106: 2710- 2715.
［6］ Januzzi J, Jang IK. Fundamental concepts in the pathobiology of heparin- induced thrombocytopenia［J］. J Thromb Thrombolysis, 2000, 10: 7- 11.
［7］ Kreimann M, Brandt S, Krauel K, et al. Binding of anti- platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4［J］. Blood, 2014, 124: 2442- 2449.
［8］ Hopper JL, Treloar SA, de Klerk NH, et al. Australian twin registry: a nationally funded resource for medical and scientific research, incorporating match and WATCH［J］. Twin Res Hum Genet, 2006, 9: 707- 711.
［9］ Krzych LJ, Nowacka E, Knapik P. Heparin- induced thrombocyto- penia［J］. Anaesthesiol Intensive Ther, 2015, 47: 63- 76.
［10］ Warkentin TE. Heparin- induced thrombocytopenia: pathogenesis and management［J］. Br J Haematol, 2003, 121: 535- 555.
［11］ Otis SA, Zehnder JL. Heparin- induced thrombocytopenia: current status and diagnostic challenges［J］. Am J Hematol, 2010, 85: 700- 706.
［12］ 斯晓燕， 赵永强． 肝素诱导的血小板减少症［J］． 中华内科杂志， 2008， 47： 71- 72．
［13］ Vo QA, Lin JK, Tong LM. Efficacy and safety of argatroban and bivalirudine in patients with suspected heparin- induced throm- bocytopenia［J］. Ann Pharmacother, 2015, 49: 178- 184.
［14］ Grouzi E. Update on argatroban for the prophylaxis and treatment of heparin- induced thrombocytopenia type Ⅱ［J］. J Blood Med, 2014, 5: 131- 141.
［15］ 王 钰， 施万印． 抗凝、 抗血小板及溶栓药物的合理应用［J］． 介入放射学杂志， 2011， 20： 76- 81．
［16］ 王勇德， 孙中华， 钟明惠， 等． 肝素诱导血小板减少症一例的循证治疗［J］． 中华内科杂志， 2007， 46： 678- 680．
［17］ Iluonakhamhe E, Ibekwe O, Samuel S, et al. Plasmapheresis may be an option in urgent management of heparin- induced thrombocy- topenia in the setting of acute intracerebral hemorrhage［J］. Neurocrit Care, 2015, 22: 140- 145.
［18］ Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin- induced thrombocytopenia: American college of chest physicians evidence- based clinical practice guidelines （8th edition）［J］. Chest, 2008, 133: 340S- 380S.
［19］ Hopkins CK, Goldfinger D. Platelet transfusions in heparin- induced thrombocytopenia: a report of four cases and review of the literature［J］. Transfusion, 2008, 48: 2128- 2132.
相似文献/References:
[1]赵 璐,吴 琳.介入栓塞在儿科血管瘤治疗中的应用现状[J].介入放射学杂志,2013,(12):1059.
ZHAO Lu,WU Lin..The current clinical application of interventional embolization for the treatment of hemangiomas in pediatrics[J].journal interventional radiology,2013,(02):1059.